Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurosurgical and prehospital timing in severe traumatic brain injury: Insights from the prospective Resuscitation Outcomes Consortium hypertonic saline trial.

The journal of trauma and acute care surgery·2026
Same author

Hospital Medicaid payer mix associated with inpatient mortality following traumatic brain injury.

The journal of trauma and acute care surgery·2026
Same author

Physiology-informed machine learning for patient-level surgical decision-making in severe traumatic brain injury: Multicenter model development with external validation.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

Combination of Albumin and Cilostazol Improves Outcomes in a Rodent Model of Aneurysmal Subarachnoid Hemorrhage.

Neurocritical care·2026
Same author

Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.

Neurosurgical review·2026
Same author

Incidence and outcomes of unplanned escalation-of-care complications for patients with traumatic brain injury.

Clinical neurology and neurosurgery·2026

Related Experiment Video

Updated: Jul 8, 2026

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients
09:44

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients

Published on: April 12, 2011

Myasthenia gravis crisis.

Eric M Bershad1, Eliahu S Feen, Jose I Suarez

  • 1Division of Neurocritical Care, The Neurological Institute, University Hospitals Case Medical Center, Department of Neurology, Case Western Reserve University, Cleveland, Ohio, USA.

Southern Medical Journal
|January 8, 2008
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis crisis (MGC) is a severe exacerbation of myasthenia gravis (MG) requiring mechanical ventilation. Prompt diagnosis and management, including immunotherapy and trigger removal, have improved outcomes, with mortality now at 4-8%.

Related Experiment Videos

Last Updated: Jul 8, 2026

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients
09:44

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients

Published on: April 12, 2011

Area of Science:

  • Neurology
  • Immunology
  • Critical Care Medicine

Background:

  • Myasthenia gravis (MG) is an autoimmune neuromuscular disease affecting approximately 18,000 individuals in the US.
  • It is characterized by antibodies targeting acetylcholine receptors, leading to postsynaptic membrane destruction at the neuromuscular junction.
  • Myasthenia gravis crisis (MGC) represents a critical exacerbation of MG necessitating mechanical ventilation.

Purpose of the Study:

  • To define Myasthenia gravis crisis (MGC) and its diagnostic considerations.
  • To outline the acute management strategies for MGC.
  • To report on the current outcomes and mortality rates associated with MGC.

Main Methods:

  • Review of clinical definitions and diagnostic criteria for MGC.
  • Description of supportive and specific therapeutic interventions for MGC.
  • Analysis of recent mortality data for patients experiencing MGC.

Main Results:

  • MGC diagnosis should be considered in patients with unexplained respiratory failure.
  • Effective management involves supportive care, mechanical ventilation, plasma exchange or IV immunoglobulin, and trigger factor removal.
  • Significant improvements in patient outcomes have led to a reduced mortality rate of 4-8%.

Conclusions:

  • MGC is a serious but manageable complication of myasthenia gravis.
  • Early recognition and aggressive treatment are crucial for improving patient survival.
  • Advances in critical care and immunotherapy have positively impacted MGC outcomes.